Extracorporeal membrane oxygenation for systemic lupus erythematosus: An ELSO registry analysis

The success of extracorporeal membrane oxygenation (ECMO) in treating Systemic Lupus Erythematosus (SLE) and the risk factors associated with mortality remain uncertain. <i>Methods:</i> We describe the survival outcomes at discharge of the largest SLE cohort on ECMO support. We performed a retrospective cohort study of the Extracorporeal Life Support Organization registry database from 2012 to 2022. Pediatric and adult survivor groups were analyzed using descriptive statistics for the primary study outcome of survival to hospital discharge. Risk predictors for survival were determined by logistic regression.<i>Results:</i> We included 48 children and 368 adults with SLE. Overall, 198 patients (54%) survived to hospital discharge, with a survival of 52% and 47% of pediatric and adult patients, respectively.<i>Conclusion:</i> We conclude that ECMO can be considered a life supporting strategy in pediatric and adult SLE patients.